IGF1 and cancer: Abnormalities in lipid metabolism have been linked to several tumorigenic processes, including cancer progression and metastasis.366 Luteolin, functioning as a fatty acid synthase inhibitor, obstructs the de novo biosynthesis of long-chain fatty acids and exerts its anticancer effects in CRC by modulating a multitude of tumor signaling pathways, including IGF-1, Keap1-Nrf2-ARE, and Wnt-β-catenin.367